EMA Authorised: Rivastigmine Actavis (rivastigmine hydrogen tartrate) — Actavis Group PTC ehf

View source ↗

Summary

EMA authorised Rivastigmine Actavis (rivastigmine hydrogen tartrate) for dementia-related indications including Alzheimer's disease and Parkinson's disease. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Parkinson Disease

Drugs mentioned

• Rivastigmine Actavis (rivastigmine)

Snippet

Status: Authorised. Therapeutic area: Dementia;Alzheimer Disease;Parkinson Disease. MAH: Actavis Group PTC ehf. Decision date: 13/06/2025